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thrombosis.NYHA functional class, LV function, site of valve, and
recurrent episodes were major determinants of successful
thrombolysis.
Prevalence of CAD and its risk factors in patients
of rheumatic heart disease undergoing valvular
surgery
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Kamal Sharma, Sharad Jain
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Background: Presence of clinically significant coronary artery
disease (CAD) in patients undergoing valvular surgery is common
cause of post-operative complication and poor outcome.The cur-
rent study was designed to study overall prevalence of CAD andits
risk factors in patients affected by rheumatic heart disease (RHD).
Methods: A total of 757 consecutive rheumatic heart disease pa-
tients planned for valvular surgery who had undergone routine
coronary angiography in our Institute were examined. Presence of
clinically significant CAD was considered if one or more arteries
showed  50% stenosis in angiographic profile. Patients were
randomly divided into two groups e Group A (RHD with CAD) and
Group B (RHD without CAD), and were screened for the presence
of various coronary artery disease risk factors.
Results: The overall prevalence of CAD in the patients undergoing
valvularsurgery was 9.11%. The incidence of CAD in patients with
mitral, aortic and double valve replacement were 24.13%, 10.81%
and 6.15% respectively. The presence of smoking habit (33.3% vs.
20.9%) (p¼0.02), diabetes (24.6% vs. 3.1%) (p<0.0001), hypertension
(21.7% vs. 6.8%) (p<0.0001) and family history of CAD (17.4% vs.
8.3%) (p<0.02) was significantly higher in group A as compared to
group B. In Group A, single vessel disease, double vessel disease
and triple vessel diseasewere seen in 55.1%, 29% and 15.9 % cases
respectively.In RHD patients, the most commonly involved vessel
was LAD (left anterior descending artery) (63.7% overall and 30.4%
alone) followed by LCX (left circumflex artery) (59.04%) and RCA
(right coronary artery) (34.7%).
Conclusion: Prevalence of CAD in patients with RHD in Gujarat,
India waslower than that in western countries and was seenmore
frequently in patients with mitral valve disease. Single vessel
involvement, mostly LAD was more common among these pa-
tients. CAD in RHD patients was associated with the presence of
multiple identifiable coronary risk factors.
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Background: Thrombosis is a serious and life threatening
complication following cardiac valve replacement and is a com-
mon cause of referral to the higher centre for intervention.
Although surgery has been described as the traditional choice of
therapy for the PVT all over the world, thrombolytic therapy is a
promising alternative to valve re-operation in PVT.
Methods: Twelve consecutive patients (6males, 6 females) (2 AVR,
9 MVR and 1 DVR) were included in the study from January 2013 to
January 2014. Mean age were 29±10 years. Diagnosis is confirmed
both by TTE and fluoroscopy. Mean gradient of patients with
mitral PVT were 24.4±4.86 and for aortic PVT was 43.3±13.1. All
patients were taking Acenocumarol derivatives. INR on presen-
tation was 1.79±0.34 and 2.53±1.31 for aortic and mitral PVT.
Thrombus burden was measured in all patients by TEE. Ten-
ecteplase is given at a dose of 0.5mg/ kg bolus in all the patients
with clinical and Echocardiographic examinations repeated at 6
and 24 hours after starting thrombolytic therapy. Doppler echo-
cardiography was the primary method to follow for response to
therapy.
Results: Thrombolytic therapy was successful in all the patients.
Mean gradient decrease to 10.3±3.4mmhg and 5.7±3.1 mmhg at 6
and 24 hours for mitral valve (p<0.001) and 8.2±4.6 mmhg and
5.8±2.5 mmhg for aortic valve (p¼<0.001). Leaflets movements
were complete in 7 and partial in 5 patients. Thrombus burden
significantly reduced in all the patients. Two patients had CVA
(infarct) and 1 had large sheath site hematoma. None of the pa-
tients expired. At 6 months follow up, Mean gradient were
8.3±2.8mmhg and 10.3±4.72mmhg for mitral and aortic valve. All
patients were asymptomatic with no complications on follow up.
Conclusion: Present study demonstrates that Tenectaplase is a
safe, feasibile and effective thrombolytic treatment for patients
with PVT and should be considered as first line therapy for pros-
thetic heart valve thrombosis.
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Background: Pure HR reduction with Ivabradine without unde-
sirable hemodynamic side effect associated with B-blockers may
be better for symptomatic improvement in mitral stenosis (MS)
patients with normal sinus rhythm (NSR).
Methods: 100 mitral stenosis patients with NSR were randomized
in a ratio of 1:1 to receive either Ivabradine (5mg-BD) or atenolol
(50mg-OD) for 12 weeks. Clinical assessment, TMT and echo-
Doppler evaluation was done to compare efficacy and side effect
of two drugs.
Results: Mean dose of Ivabradine and Atenolol was 6.05±1.25mg
and 60±26.7 mg respectively at 12 weeks. Results are shown in
table. Resting HR reduction was similar in both groups. On TMT
peak HR reduction, increase in Total exercise duration & Time of
Symptom onset showed similar improvement in both groups.
MDG& EDG reductionwas similar in both groups. Significant RVSP
reduction was seen in Ivabradine group but not in Atenolol group.
NYHA class showed similar improvement with both drugs. Total
13 drug side effects were noticed. 2 in Ivabradine and 11 in aten-
olol group. There was 1 case of bradycardia in each group, 10 pa-
tients complained of increased fatigability with Atenolol.1 patient
had visual symptoms with Ivabradine.
Conclusion: Ivabradine is a useful alternative to B-blockers
treatment in patients with symptomatic mitral stenosis, having
efficacy similar to B-blockers with lower side effects.
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